Literature DB >> 14502658

What causes mental dysfunction in Parkinson's disease?

Murat Emre1.   

Abstract

Parkinson's disease (PD) is frequently associated with mental dysfunction. Domain-specific cognitive deficits are ubiquitous, and although they may not be clinically apparent in all patients, they are demonstrable by neuropsychological testing. Dementia is less frequent but is present significantly more in PD patients than in controls, with a cumulative prevalence rate up to 40% and up to six-fold increased incidence. Cognitive impairment mainly involves executive and visuospatial functions; memory is secondarily impaired with relatively preserved recognition. Qualitatively, the neuropsychological profile of dementia encompasses the same type of deficits found in nondemented PD patients. The dementia seen in PD, therefore, can be described as a dysexecutive syndrome combined with visuospatial dysfunction and behavioural symptoms. Dopaminergic, noradrenergic, serotoninergic, and cholinergic deficits have all been described as the underlying neurochemical impairment, but the strongest evidence exists for a cholinergic dysfunction. Involvement of brainstem nuclei, limbic structures, and cerebral cortex have been suggested as the site, and Lewy body (LB) degeneration and Alzheimer-type changes as the type of pathology underlying the mental dysfunction in PD. Although there is still some controversy as to the site and type of pathology, recent evidence suggests that LB-type degeneration in limbic structures and cerebral cortex, with consequent synaptic and cell loss, is the main pathological state associated with dementia in PD. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502658     DOI: 10.1002/mds.10565

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  46 in total

1.  Amyloid imaging of Lewy body-associated disorders.

Authors:  Erin R Foster; Meghan C Campbell; Michelle A Burack; Johanna Hartlein; Hubert P Flores; Nigel J Cairns; Tamara Hershey; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most?

Authors:  Francesca Di Biasio; Nicola Vanacore; Alfonso Fasano; Nicola Modugno; Barbara Gandolfi; Francesco Lena; Giovanni Grillea; Sara Pietracupa; Giovanni Caranci; Stefano Ruggieri
Journal:  J Neural Transm (Vienna)       Date:  2011-12-13       Impact factor: 3.575

Review 3.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 4.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

5.  Metabolic brain networks associated with cognitive function in Parkinson's disease.

Authors:  Chaorui Huang; Paul Mattis; Chengke Tang; Kenneth Perrine; Maren Carbon; David Eidelberg
Journal:  Neuroimage       Date:  2006-11-17       Impact factor: 6.556

Review 6.  Decision-making cognition in neurodegenerative diseases.

Authors:  Ezequiel Gleichgerrcht; Agustín Ibáñez; María Roca; Teresa Torralva; Facundo Manes
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

7.  Dream features in the early stages of Parkinson's disease.

Authors:  Paulo Bugalho; Teresa Paiva
Journal:  J Neural Transm (Vienna)       Date:  2011-06-30       Impact factor: 3.575

Review 8.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

9.  Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).

Authors:  Oliver Riedel; Jens Klotsche; Annika Spottke; Günther Deuschl; Hans Förstl; Fritz Henn; Isabella Heuser; Wolfgang Oertel; Heinz Reichmann; Peter Riederer; Claudia Trenkwalder; Richard Dodel; Hans-Ulrich Wittchen
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.